TY - JOUR
T1 - A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
AU - Cherng, Hua Jay J.
AU - Chuang, Hubert H.
AU - Steiner, Raphael
AU - Fayad, Luis
AU - Strati, Paolo
AU - Nair, Ranjit
AU - Hagemeister, Fredrick
AU - Nastoupil, Loretta J.
AU - Lee, Hun Ju
AU - Neelapu, Sattva S.
AU - Flowers, Christopher R.
AU - Samaniego, Felipe
AU - Rodriguez, Maria
AU - Macapinlac, Homer A.
AU - Feng, Lei
AU - Westin, Jason
N1 - Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Many patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will not respond to platinum-containing salvage chemotherapy. Predicting treatment failure earlier could help clinicians minimize chemotherapy toxicities for non-responders in favor of other treatments. We conducted a pilot study where 2 early PET/CTs were obtained on days 4 (D4) and 21 (D21) of cycle 1 (C1) of salvage therapy for DLBCL. Twenty-five patients were enrolled and have evaluable data. Ten (40%) had an unplanned therapy change after C1 and before end-of-treatment (EOT) evaluation due to treatment failure on early PET/CT as interpreted by the treating physician. Early PET/CT response at D4 or D21 was not associated with EOT response in evaluable patients. Disease specific survival was longer for patients with a persistent response on both D4 and D21 (p = 0.042). Early PET/CT may predict salvage chemotherapy failure and could inform future clinical trials investigating early therapy change to non-chemotherapy treatments.
AB - Many patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will not respond to platinum-containing salvage chemotherapy. Predicting treatment failure earlier could help clinicians minimize chemotherapy toxicities for non-responders in favor of other treatments. We conducted a pilot study where 2 early PET/CTs were obtained on days 4 (D4) and 21 (D21) of cycle 1 (C1) of salvage therapy for DLBCL. Twenty-five patients were enrolled and have evaluable data. Ten (40%) had an unplanned therapy change after C1 and before end-of-treatment (EOT) evaluation due to treatment failure on early PET/CT as interpreted by the treating physician. Early PET/CT response at D4 or D21 was not associated with EOT response in evaluable patients. Disease specific survival was longer for patients with a persistent response on both D4 and D21 (p = 0.042). Early PET/CT may predict salvage chemotherapy failure and could inform future clinical trials investigating early therapy change to non-chemotherapy treatments.
KW - Diffuse large B-cell lymphoma
KW - end of treatment
KW - positron emission tomography/computed tomography
KW - real-time response assessment
KW - salvage chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=85113572959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113572959&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.1971223
DO - 10.1080/10428194.2021.1971223
M3 - Article
C2 - 34435552
AN - SCOPUS:85113572959
SN - 1042-8194
VL - 63
SP - 74
EP - 83
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -